Helsinki, December 2024 – MVision AI is proud to announce that our flagship product, Contour+, has successfully transitioned from the EU Medical Devices Directive (MDD) to the new EU Medical Device Regulation (MDR).
The transition to the MDR regulation is a crucial step that ensures our products meet the highest standards of safety, performance, and quality in an evolving regulatory landscape. Under the MDD, medical devices were subject to certain standards, but the MDR introduces stricter requirements in areas such as clinical evaluation, post-market surveillance, and traceability. For MVision AI, this transition ensures that Contour+ continues to comply with these enhanced regulatory requirements, strengthening the product’s reliability and trustworthiness in the European market.
This transition confirms Contour+’s continued safety, performance, and quality, reinforcing our ongoing mission to advance cancer care worldwide by providing radiation oncology professionals with the most innovative and reliable tools available.
Successfully transitioning to the new EU Medical Device Regulation (MDR) is a significant achievement for MVision AI and a reflection of our unwavering commitment to innovation and patient-centric care,” said Saad Ullah Akram, CEO of MVision AI. “This milestone not only ensures that our solutions continue to meet the highest standards of safety and performance but also enables us to expand the adoption of our Guideline-Based Segmentation (GBS™) solution, including Contour+, Guide, and Verify, across Europe and beyond. It’s a proud moment for our team as we continue to push the boundaries of what’s possible in the field of radiation therapy.
About MVision AI
MVision AI is a leading provider of AI-powered solutions for radiation therapy treatment planning. Our mission is to empower Radiation Oncology professionals with cutting-edge technology to streamline workflows, enhance treatment quality, and facilitate more patient-focused care. With a commitment to innovation and excellence, MVision AI continues to advance cancer care through the power of AI.